LDL-C lowering in patients treated with bempedoic acid in a real-world cohort

20260 citationsJournal Articlegold Open Access

Authors

James O. Nelson

LeAnne Bloedon · Esperion Therapeutics (United States)

Dave Lewandowski

Muthiah Vaduganathan · Brigham and Women's Hospital

Maryam Ajose

Mac Bonafede

Evelyn Sarnes · Esperion Therapeutics (United States)

Abstract

Patients initiating BA and BA + EZE experienced early and sustained LDL-C improvements. The greatest reductions were in patients with continuous use and patients with no evidence of prior statin use, underscoring the importance of long-term adherence and treating patients not on statin therapy.

Topics & Keywords

Lipoproteins and Cardiovascular Health Cholesterol and Lipid Metabolism Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Atherosclerosis Plus

Volume 63, pp. 58-66

DOI: 10.1016/j.athplu.2026.01.007

Field-Weighted Citation Impact: 0.00